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Head and neck squamous cell cancer (HNSCC) is the sixth most common cancer world-
wide. Two-thirds of affected patients present with advanced stage III or IV disease. De-
spite advances in combined modality therapy, involving surgery, radiotherapy, and che-
motherapy, the 5-year survival rate remains at 40%. Concomitant external beam radiation 
and chemotherapy are more effective than radiotherapy alone.  
 
Nuclear medicine utilizes potential radiolabeled carriers in the diagnostics and therapy of 
cancer. Short-range Auger-electron emitters, such as 111In and 114mIn, tagged with a drug, 
molecule, peptide, protein, new class of trifunctional somatostatin analog or nanoparticles 
placed in close proximity to nuclear DNA represent a fascinating alternative for treating 
cancer. In this thesis, we studied the usefulness of 111In-BLMC in the diagnostics and po-
tential therapy of HNSCC using in vitro HNSCC cell lines, in vivo nude mice, and in vivo 
HNSCC patients. 
 
In vitro experiments with HNSCC cell lines were performed using the 96-well plate clono-
genic assay based on limited dilutions. The sensitivity for external beam radiation, BLM, 
111In-BLMC, and 111InCl3 was studied using several HNSCC cell lines. The influence of 
BLM and 111In-BLMC on the cell cycle was investigated by flow cytometry. 
 
In in vivo nude mice xenograft studies, the activity ratios of 111In-BLMC were obtained in 
gamma camera images. Another purpose was to examine the effect of 111In-BLMC in 
HNSCC xenografts. In in vivo patient studies, we determined the tumor uptake of 111In-
BLMC by gamma camera and the radioactivity and proliferative activity from tumor sam-
ples using 111In-BLMC with specific activity of 75, 175, or 375 MBq/mg BLM. The S val-
ues, i.e. absorbed dose in a target organ/region per cumulated activity in a source or-
gan/region, were simulated for 111In and 114mIn.  
 
In vitro studies expressed the variation of sensitivity for external beam radiation, BLM, 
and 111In-BLMC between HNSCC cell lines. IC50 values for BLM were 1.6-, 1.8-, and 2.1-
fold higher than 111In-BLMC (40 MBq/mg BLM) with three HNSCC cell lines. Specific 
111In activity of 40 MBq/mg BLM was more effective in killing cells than specific 111In 
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activity of 195MBq/mg BLM (p=0.0023). 111InCl3 alone had no killing effect. The percent-
age of cells in the G2/M phase increased after exposure to BLM and especially to 111In-
BLMC in the three examined cell lines, indicating a G2/M block. Tumor-seeking behavior 
was shown in the in vivo imaging study of xenografted mice. BLM and 111In-BLMC were 
more effective than NaCl in reducing xenografted tumor size in HNSCC. The uptake ratios 
received from gamma images in the in vivo patient study varied from 1.2 to 2.8 in malig-
nant tumors. However, the uptake of 111In-BLMC was unaffected by increasing the in-
jected activity. A positive correlation existed between 111In-BLMC uptake, Ki-67/MIB ac-
tivity, and number of mitoses. Regarding the S values, 114mIn delivered a 4-fold absorbed 
radiation dose into the tumor compared with 111In, and thus, the cytotoxicity of Auger-
electron therapy might be more effective with 114mIn-BLMC than with 111In-BLMC at the 
DNA level. 
 
Auger-electron emitters, such as 111In and theoretically 114mIn, represent an attractive alter-
native in the treatment of advanced HNSCC. Further studies are needed to develop a ra-
diopharmaceutical agent with appropriate physical properties of the radionuclide and a 
suitable carrier to bring it near the targeted tissue.  
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AC  adenocarcinoma 
AUC  area under the curve 
BF  benign fibroma 
BLM  bleomycin 
CHART   continuous hyperfractionated accelerated radiotherapy 
CT  computed tomography 
D  mean inactivation dose 
DI  DNA index 
DMEM  Dulbecco´s modified Eagle medium 
DNA  deoxyribonucleic acid 
EC  ectron capture 
ECT  electro-chemotherapy   
EDTA  ethylenediamine-tetra-acetic acid 
EP  electric pulse 
eV  electron volt 
FBS  fetal bovine serum 
FDG  fluorodeoxyglucose 
G0  resting phase of cell cycle 
G1  interphase of cell cycle 
G2/M  premitotic and mitotic phase of cell cycle 
Gy  gray, unit of absorbed dose 
HDR  high dose rate 
HNSCC  head and neck squamous cell carcinoma 
HPF  high-power field 
HPV  human papilloma virus 
IC20-90  drug concentration causing 20-90% inhibition of clonogenic 
survival 
IC  internal conversion 
ICRP  International Commission on Radiation Protection  
ID  injected dose 
IMRT  intensity modulated radiation therapy 
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111In-BLMC  indium-111-bleomycin complex 
LDR  low dose rate 
LET  linear energy transfer 
LQ  linear-quadratic 
MBq  megabecquerel 
MCD  multichannel detector 
MIRD  medical internal radiation dose 
MRT  mean residence time 
NaCl  sodium chloride 
NL  neurilemmoma 
PDR  pulsed dose rate 
PE  plating efficiency 
PET  positron emission tomography 
RBE  relative biological effectiveness 
ROI  region of interest 
RTS  relative tumor size 
SCC  squamous cell carcinoma 
SCID  severe combined immunodeficiency 
SCLC small cell lung carcinoma 
SD standard deviation 
SF survival fraction 
SF2  survival fraction after a single radiation dose of 2 Gy 
SPECT single photon emission computed tomography 
S value absorbed dose in a target organ/region per cumulated activity in 
source organ/region 
T1/2,biol   biological half-life 
T1/2,eff   effective half-life 
T1/2,phys   physical half-life 
TD   doubling time 
TLC  thin-layer chromatography 
TNM  tumor, node, metastasis 
T/non-T  tumor fraction divided by non-tumor fraction 






Head and neck squamous cell cancer (HNSCC) is the sixth most common cancer in the 
world (Parkin et al. 2005). The International Agency for Research on Cancer estimates that 
globally HNSCC accounted for more than 600 000 cases in 2002 (GLOBOCAN 2002, 
Parkin et al. 2005). 
 
In general, surgery or radiotherapy is the main treatment regimen for stage I and II 
HNSCCs. Worldwide, approximately two-thirds of HNSCCs are in stage III/IV at presen-
tation. Locally advanced HNSCC patients treated with surgery in combination with radio-
therapy are known to be at risk of locoregional recurrence in 30% and distant metastases in 
up to 25% of cases (Laramore et al. 1992, Spector et al. 2001). The 5-year overall survival 
rate of stage III and IV disease remains at 40%. The addition of chemotherapy concomi-
tantly to radiotherapy has improved patient outcome. Several meta-analyses have been per-
formed comparing concomitant chemoradiation to radiation alone in treatment of advanced 
HNSCC (Pignon et al. 2000, Bourhis et al. 2007, Pignon et al. 2007). Two large-scale pro-
spective randomized trials comparing concomitant cisplatin and irradiation versus radio-
therapy alone demonstrated significant improvement in outcome of concomitantly treated 
locally advanced HNSCC patients (Bernier et al. 2004, Cooper et al. 2004). 
 
Despite combined-modality approaches, including surgery, external radiation, and chemo-
therapy, the risk of failure is high. We need tools to prevent local recurrences and eradicate 
micrometastases (Colnot et al. 2004).  A radionuclide tagged with a drug, molecule, pep-
tide, protein, new class of trifunctional somatostatin analog, or a nanoparticle, offers a po-
tential means for diagnostics and therapy of cancer. After 1971, the official inception of 
nuclear medicine, this field has evolved rapidly (Graham and Metter 2007). 
 
Radioactive isotopes are called radionuclides. They are unstable atoms that disintegrate 
randomly with the emission of ionizing radiation (Ahonen et al. 2003). They can be pro-
duced in many nuclear reactions, and thus, in industrial nuclear reactors and particle accel-
erators. In 2005, a total of 125 radionuclides were available in the United States, but 20 of 
them were being compounded under the state-regulated practice of medicine and pharmacy 
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(Silberstein 2005). The physical characteristics of a radionuclide, including gamma energy 
and physical half-life, determine its suitability for imaging. Gamma-rays emitting radionu-
clides, such as 99mTc, 111In, 153Sm, 123I, and 170 Er, may be imaged with a gamma camera 
(SPECT), while positron emitters, such as 11C, 13N, and 15O, can be identified by positron 
emission tomography (PET). 
 
In addition to diagnosis of cancer and assessment of treatment response, radionuclide-
based techniques allow one to monitor the biodistribution of release and kinetics. The 
quantitative nature of the images enables the site of receptors in the brain in Alzheimer´s 
disease, Tourette´s syndrome, and epilepsy to be recognized (Chappell et al. 1993, De 
Lanerolle et al. 1997, Mathieu-Kia et al. 2001). Radionuclides have been successfully ap-
plied to the assessment of myocardial viability, function of kidneys and lungs, and identifi-
cation of locations of inflammation, atherosclerosis, and thrombosis (Arrighi and Dilsizian 
2006, Jalilian et al. 2006).  Scintigraphic studies may even be used to examine gastric 
emptying or ocular pharmacokinetics (Perkins and Frier 2004). The results of radiotargeted 
gene therapy have been encouraging in animal xenograft models (Buchsbaum 2004, 
Buchsbaum et al. 2005). 
 
Radionuclide-based therapy requires appropriate physical properties of the radionuclide, a 
suitable carrier to bring it near the targeted tissue, high affinity and specificity for tumor 
cells, and a known of radiation decay on the cell cycle and DNA (Kassis 2005, Kassis and 
Adelstein 2005). Interesting emissions are composed of energetic α- and β-particles or low-
energy particles, such as low-energy Auger-electrons.  
 
Van Dongen et al. demonstrated a total ablation of HNSCC and ovarian cancer xenografts 
treated with an antibody tagged with 186Re (Gerretsen et al. 1993, Kievit et al. 1997). 
Radioactive cisplatin (191Pt) reduced the tumor size more than cisplatin alone in nude mice 
(Areberg et al. 2001). 
 
Several preclinical investigations have been done to produce a potent radiopharmaceutical 
agent for therapy (Börjesson 2003, Börjesson 2004, Perk et al. 2005). Current radionuclide 
therapy commonly uses β-emitters tagged to a monoclonal antibody. The US Food and 
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Drug Administration has approved 90Y-ibritumomab tiuxetan and 131I-tositumomab for the 
treatment of nonHodgkin´s lymphoma (DeNardo et al. 2006).  
 
Several radionuclides such as indium-111 (111In) emit also low-energy Auger-electrons 
with a short range, from one nanometer up to ~ 0.5 µm, causing chromosome aberrations 
inside the cell (Sastry and Rao 1984, Hou et al. 1992). Auger-electrons are atomic orbital 
electrons emitted as an alternative to x-ray emission after electron capture (EC), and they 
deposit their energy in the vicinity of the decay site (Sorenson and Phelps 1987, Howell 
1992). The estimated absorbed dose rate at the center of a cell released by 111In is 18 times 
higher when the radioactivity impacts the nucleus rather than the cell membrane (Faraggi 
et al. 1994).  
 
Bleomycin (BLM) is a mixture of chemotherapeutic glycopeptidic antibiotics produced by 
a strain of Streptococcus verticillus (Umezava et al. 1966a). It binds to DNA, causing sin-
gle- and double-strand breaks (Kuo and Haidle 1973, Iqbal et al. 1976, Burger et al. 1981, 
Cheong and Iliakis 1997). BLM may be used in treatment of locally advanced and metas-
tatic HNSCC, especially in combination with such drugs as cisplatin and 5-fluorouracil. 
 
111In tagged to BLM easily forms 111In-bleomycin complex (111In-BLMC) (Thakur et al. 
1973).  111In-BLMC is stable in vitro and in vivo and is not toxic to bone marrow (Hou et 
al. 1984b). Hou et al. demonstrated in small cell lung cancer cells by autoradiography that 
111In-BLMC is localized 78.3% in the nucleus and nuclear membrane (Hou and Maruyama 
1992). The anti-tumor effect of 111In-BLMC has been expressed in human small cell lung 
cancer (SCLC) cell lines (Hou et al. 1989a) and in glioma-bearing nude mice (Hou et al. 
1985). 111In-BLMC has a tumor-seeking behavior expressed in patients with HNSCC 
(Kairemo et al. 1996a) and gliomas (Korppi-Tommola et al. 1999). 
 
This thesis examines in vitro and in vivo with xenografted mice the antitumor effect of 
111In-BLMC in HNSCC. Cellular sensitivity to BLM and external beam radiation was 
compared to observe possible co-sensitivity and cross-resistance patterns in HNSCC cell 
lines. In the patient study, mitoses, proliferation, and tumor targeting with 111In-BLMC of 
three different 111In activities were investigated in HNSCC tissue. Finally, based on human 
imaging study, a phantom model derived from CT images was built to examine the actual 
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absorbed radiation doses of 111In-BLMC and 114mIn-BLMC, aiming to find a proper ra-
dionuclide for radiochemotherapy (Table 1). 
 
Table 1. Summary of study design. 
 
 
In vitro cell models 
 
In vivo models 
 
In silico models 
 
Generation of radio-
sensitive cell lines 
 
 
Generation of radio- and 
chemosensitive animal 
tumor model for HNSCC 
 
Building a human phan-
tom with a HNSCC tumor 
and metastasis model 
 
Generation of chemo-




Generation of geometric 
factors for HNSCC pri-
mary and metastasic tu-






2. Review of the literature 
 
2.1. Epidemiology of head and neck squamous cell cancer (HNSCC)   
 
The majority of HNSCCs (~90%) originate from squamous cell mucosa ranging from 
poorly differentiated to well-differentiated tumors (Zarbo and Crissman 1988). Keratin or 
“keratin pearls” in the depths of the epithelium on histological samples are characteristic of 
SCC (Zarbo and Crissman 1988). Premalignant lesions of HNSCC are erythroplakia (Gug-
genheimer et al. 1989) and leukoplakia (Walkdron and Shafer 1975). HNSCCs include 
squamous epithelial malignant tumors arising from the mucosa of the oral cavity, pharynx, 
larynx, nasal cavity, paranasal sinuses, and salivary glands, and from the skin of the face. 
HNSCCs are classified according to the TNM (tumor, node, metastasis) staging system 
established by the International Union Against Cancer (UICC) (Sobin and Wittekind 
2002). The status of the lymph nodes of the neck has been shown to be the most important 
prognostic factor for HNSCC (Leemans et al. 1993, Léon 2000, Spector et al. 2001). 
 
Tobacco smoking is regarded as a significant risk factor for carcinogenesis, especially in 
oral and pharyngeal cancers (Forastiere and Kock 2001, Warnakulasuriya et al. 2005). 
High alcohol consumption is another important risk factor for the development of HNSCC 
(Blot 1992, Licitra et al. 2002, Walker et al. 2003). There is mounting evidence that epige-
netic alterations of some genes may be related to the carcinogenetic effect of tobacco and 
such alcohol metabolites as acetaldehydes (Peters et al. 2005, Kraunz et al. 2006b, Marsit 
et al. 2006). A hereditary family history of cancer may play a role in the development of 
HNSCC (Copper et al. 1995, Foulkes et al. 1995). A diet containing low amounts of fresh 
fruits and vegetables is associated with an increased risk of HNSCC (De Stefani et al. 
1999). Low dietary intake of folate is a well-known risk factor for HNSCC (Kraunz et al. 
2006a). Human papilloma viruses (HPVs) have been shown to be involved in the carcino-
genesis of HNSCC, especially in the oropharynx (Chen et al. 2005, Syrjänen 2005, Fakhry 
and Gillison 2006). 
 
Worldwide incidence rates of HNSCC vary highly. The age-standardized incidence of la-
ryngeal cancer in northern Europe was 4.3 per 100 000 in men and 0.7 per 100 000 in 
women in 2002, whereas in southern Europe the corresponding rates were 10.9 and 0.7 per 
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100 000. The highest incidence of oral cancer, 31.5 per 100 000 men, is found in Melane-
sia compared with 9.2 per 100 000 men in southern Europe and to 5.3 per 100 000 men in 
northern countries (GLOBOCAN 2002, Parkin et al. 2005). 
 
According to the Finnish Cancer Registry in 2006, the age-adjusted incidence of HNSCC 
in men was 10.7 per 100 000. In women, the corresponding figure was lower, 4.4 per 100 
000 (Finnish Cancer Registry 2006). The age-adjusted mortality rate of HNSCC per 100 
000 in 2006 was 3.1 in men and 1.1 in women. 
  




Surgery and radiotherapy are the cornerstones of treatment of early-stage HNSCC (Stage I 
or II), with locoregional control rates of 70-80%. Advanced stage disease (Stage III or IV) 
in turn is treated with a combination of surgery and radiation or chemoradiation. Since 
1960, the development of reconstructive surgery and particularly during the 1970s the de-
velopment of pedicle and free flaps were huge leaps forward in the functional outcome of 
patients. The pectoralis major myocutaneous flap described by Aryian in 1979 is still in 
use. Progress of surgical techniques, including microsurgery, has rendered it possible to re-
construct large defects in the HNSCC region and get a better functional result.  
 
The presence of a single lymph node on either ipsilateral or the contralateral side of the 
neck reduces the 5-year survival rate to only half of that for N0 patients. Modified, selec-
tive, or radical neck dissection should be carried out if metastatic lymph nodes are present 
or if there is more than a 15-20% risk of occult disease (Chin et al. 2006).  
 
Unfortunately, the overall survival for advanced-stage cases at 5 years is still only 30-50% 
(Chin et al. 2006). More complex management strategies have been developed to improve 
disease control and survival (St John et al. 2006). However, normal tissue morbidity is an 




2.2.2. External beam radiotherapy 
 
Radiotherapy as a single modality treatment is a primary treatment form in some early-
stage HNSCCs. In addition, an advantage of combined surgery and radiation has been 
demonstrated, among others, by Fletcher and Evers already in 1970. Radiation therapy is 
often used after surgery as a curative adjuvant treatment. Developments in radiotherapy 
delivery have improved the prognosis of HNSCC. However, many patients are still diag-
nosed when disease has advanced locally or regionally to such an extent that operative 
treatment is no longer sufficient or feasible. Radiation and medical oncology may still help 
these patients as a palliative treatment modality. 
 
In conventional fractionated radiotherapy, 1.8-2.0 Gy is given as a single dose 5 days a 
week to a total dose of 60-70 Gy. Hyperfractionation and accelerated fractionation have 
been explored as promising types of altered fractionation (Horiot et al. 1992, Horiot et al. 
1997, Ang 1998, Bourhis et al. 2004). The concept of hyperfractionation is based on an in-
creased dose-fractionation schedule, keeping the overall treatment time unchanged 
(Bernier and Bentzen 2003). Smaller fraction doses (< 1.2 Gy) two or three times a day can 
protect slowly responding normal tissues, enabling the total dose of radiation to be raised 
by 10-15% (Ang 1998). An increased schedule and a rate of dose-accumulation exceeding 
10 Gy a week is classified as accelerated (Bernier and Bentzen 2003). The intention is to 
compensate with an altered radiation schedule the accelerated repopulation of the surviving 
clonogenic cells during fractionated radiotherapy (Gibson and Forastiere 2004). With this 
method, the overall time of radiation therapy is reduced. In continuous hyperfractionated 
accelerated radiotherapy (CHART), the total dose was reduced to 54 Gy by giving 1.5 
Gy/fraction three times a day (4-hour intervals) over 12 days.  
 
The development of computed tomography (CT)-guided three-dimensional conformal ra-
diotherapy planning has created a novel form of therapy, the intensity-modulated radiation 
therapy (IMRT), which enables more conformal dose distributions. The optimal dose dis-
tribution in the target volume allows sparing of normal tissues, decreasing sequelae (Ver-
hey 2002).  IMRT schedules have achieved successful results in the treatment of many 
types of HNSCCs (Chao et al. 2001, Xia et al. 2004, Saarilahti et al. 2005, Tenhunen et al. 
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2008). Saarilahti et al. (2005) demonstrated how IMRT effectively reduced the absorbed 




Since 1970, when the first promising HNSCC patient studies with cytotoxic drugs were 
performed, chemotherapy has belonged to the treatment regimen of advanced HNSCC 
(Bernier and Cooper 2005). 
 
Chemotherapy can be given as a single treatment and is then usually used for palliation in 
HNSCC. In treatment with a curative intent, chemotherapy has been used concomitantly 
with radiation or as an adjuvant or neoadjuvant therapy.  
 
2.2.4. Concomitant chemoradiotherapy 
 
For improving patient outcome, concurrent chemoradiotherapy has been more effective 
than neoadjuvant and adjuvant schedules (Eisenberger and Jacobs 1992, Aisner et al. 1994, 
Bourhis and Eschwege 1996, Pignon et al. 2000, Bernier and Bentzen 2003, Bourhis et al. 
2007, Pignon et al. 2007). Chemotherapeutic agents are thought to inhibit the repair of le-
thal and sublethal damage caused by radiation. They probably also radiosensitize hypoxic 
cells and synchronize tumor cells into the G2/M, which is the most radiosensitive phase of 
the cell cycle (Bernier and Cooper 2005).   
 
Pignon et al. (2000) showed in the meta-analyses an 8% survival benefit with concomitant 
chemoradiotherapy at 2 and 5 years. The benefit of adjuvant or neoadjuvant chemotherapy 
was modest. Munro (1995) reported in a meta-analysis of 54 randomized controlled trials 
that single-agent chemotherapy with concomitant radiotherapy increased survival by 
12.1% in HNSCC patients. 
 
Adelstein et al. (2000) reported a prospective randomized trial where 100 patients with 
stage III/IV HNSCC were randomized to receive 1.8-2 Gy radiation per day either without 
(Arm A) or with (Arm B) concurrent 5-fluorouracil and cisplatin. The 5-year Kaplan-
Meier estimates for overall survival for Arms A and B were 48% and 50%, respectively, 
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but a significant benefit of 11% in 5-year recurrence-free interval and 9% in distant me-
tastasis-free interval was observed. 
 
In a study by Forastiere et al. (2003), 547 stage III/IV HNSCC patients were randomized to 
three arms: induction cisplatin and 5-fluorouracil followed by radiation 2 Gy/day (Arm A), 
concurrent cisplatin and radiotherapy (Arm B), or radiotherapy alone (Arm C). Total laryn-
gectomy was used as an indication of failure of organ-sparing treatment. At 2 years, 
locoregional control for Arms A, B, and C was 61%, 78%, and 56%, respectively. Che-
motherapy reduced the development of distant metastasis by 8-9% compared with radio-
therapy alone. However, no benefit in overall survival was demonstrated.   
 
Two independent, large-scale, prospective randomized trials were published in 2004. In the 
study by Cooper et al. (2004) after resection of macroscopic HNSCC, 459 patients were 
randomized to receive either radiotherapy (Arm A) or radiotherapy plus concurrent cis-
platin (Arm B). The locoregional control at 2 years was 72% in Arm A versus 82% in Arm 
B. Disease-free survival was longer in Arm B than in Arm A, but overall survival did not 
differ significantly. The acute adverse effects of grade 3 or greater, e.g. hematologic com-
plications, vomiting and upper gastrointestinal tract problems, were observed in 34% of 
patients in Arm A and in 77% of patients in Arm B. In the study by Bernier et al. (2004), 
after curative surgery, 167 HNSCC patients were treated with either radiotherapy (Arm A) 
or radiotherapy with simultaneous cisplatin (Arm B). The Kaplan-Meier estimates for 5-
year progression-free survival in Arms A and B were 36% and 47%, and for overall sur-
vival 40% and 53%, respectively. Grade 3 or greater acute adverse effects were registered 




Before the widespread use of megavoltage external beam radiotherapy for HNSCC in the 
1960s, brachytherapy (BT) with radioactive isotopes together with surgery and orthovolt-
age x-rays were used for the treatment of head and neck cancers. BT was used as a primary 
treatment, but also for the management of previously irradiated recurrent or new primary 
tumors or neck metastases (Pernod et al. 1996, Nutting et al. 2006). After the 1960s, the 
most applied radioisotope has been 192Ir due to its mean gamma energy of 360 keV, half-
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life of 74 days, and low cost. One of the most popular implantation techniques was the so-
called plastic tube technique, where the thin, coiled platinium-coated 192Ir-wire was cut 
into suitable lengths and implanted inside the plastic tubes inserted into the tumor under 
local or general anesthesia. The technique was called manual afterloading. Since a typical 
dose rate in tumors was 10 Gy/day, 6 days were required to reach the curative dose of 60 
Gy in SCC. These techniques necessitated well-trained personnel, and the biggest disad-
vantage was radiation exposure of personnel to the handled radioisotopes. 
 
In 1970-1990, a device-based afterloading was developed and HNSCC tumors could be 
treated also with low dose rate (LDR), high dose rate (HDR), and pulsed dose rate (PDR) 
BT (Nath 1993, Puthawala et al. 2001, Ding et al. 2005, Grimard et al. 2006). Plastic tubes 
were inserted into tumors as in manual afterloading, but now the automated electronic 
devices, called afterloaders, were attached to these tubes. Based on the treatment planning 
and prescribed dose, the afterloaders were programmed to send a single very high-activity 
source, typically 137Cs, 60Co, or 192Ir, to these tubes. The source moved step-wise inside the 
tube, irradiating the tumor. The treatment times were minutes to hours, as compared with 
days with manually afterloaded 192Ir LDR BT. Due to limited tolerance of nearby healthy 
tissues, the dose needed to destroy the tumor could be not delivered in a single treatment. 
Therefore, the treatment was fractionated, i.e. given in several smaller fractions. Recently, 
implants containing radionuclides with different half-lives instead of a single source have 
been suggested for further improvement of therapeutic effect (Chen and Nath 2003). The 
long-term results of HDR BT have been similar to those of manually afterloaded LDR BT 
(Nose et al. 2004). Within the last 20 years, PDR BT has partly replaced the manually 
afterloaded 192Ir-wire and plastic tube technique since radiation exposure of personnel can 




Bleomycin (BLM) is a mixture of structurally related glycopeptide antibiotics, originally 
isolated from a strain of Streptomyces verticillus (Umezawa et al. 1966a, Umezawa et al. 
1966b). BLM is a polypeptide that has three different functional parts: 1) galactos or man-
nos derivatives, which are thought to detect tumor cells, 2) a metal-chelating part, which 
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activates the metal bound to the molecule to destroy or damage the tumor, 3) a terminal 
part, which has variable terminal amino acids causing splitting of tumor DNA. 
 
The BLM-iron complex produces oxygen radicals that bind to nuclear DNA, causing sin-
gle- and double-strand breaks (Kuo and Haidle 1973, Fujimoto 1974, Lown and Sim 1977, 
Povirk et al. 1989, Cheong and Iliakis 1997), and kills dividing cells mainly in the G2 and 
M phase (Barranco et al. 1973a, Barlogie et al. 1976). In a phase-specific schedule by Bar-
ranco et al. (1971) radiomimetic BLM acted as a cell-synchronizing agent and blocked re-
versibly the cells in G2 phase in Chinese hamster ovary cells in vitro. Despite cell-cycle 
phase specificity, BLM is not less active in plateau phase than in logarithmic growing cells 
(Barranco et al. 1973b).  However, cell-synchronizing G2 phase block findings of BLM 
have generally not been confirmed (Wenneberg 1984, Wahlberg 1987). The plasma half-
life of BLM is 2-4 hours, and it is eliminated mainly by urinary excretion (Alberts et al. 
1978). About 50% of the drug is excreted intact in the urine and the remainder undergoes 
metabolism (Dorr 1992). BLM does not accumulate in the liver, spleen, intestine, or bone 
marrow, all of which have high intrinsic hydrolase activities (Ohnuma et al. 1974, Kramer 
et al. 1978).  BLM hydrolase, which hydrolyzes the terminal carboxamide group of the 
beta-aminoalanine moiety of the BLM molecule, converts BLM into an inactive desamino 
form, probably explaining the primary mechanism of BLM resistance (Lazo et al. 1982, 
Septi et al. 1991). Another potential mechanism may be elevated DNA repair activity 
(Iqbal et al. 1976, Dar and Jorgensen 1995, Sasiadek et al. 2002).  
 
In vitro BLM has cytotoxicity against several cancer cell types, including squamous cell 
carcinoma (SCC). Considerable, even ten-fold (Urade et al. 1992) differences in sensitivity 
for BLM have been demonstrated between SCC cell lines, whereas differences in radiosen-
sitivity for external radiation are not as large (Grénman et al. 1988b, Grénman et al. 1991).  
 
BLM is not detrimental to bone marrow function and causes little nausea and vomiting. 
More than half of patients experience fever and about half of patients suffer some muco-
cutaneous toxicity effects. Less frequently, BLM causes pneumonitis and lung fibrosis, 




Clinically, BLM has been administered in combination therapies to patients with testicular 
cancer, some nonHodgkin´s lymphomas, Kaposi´s sarcoma, head and neck cancer, and 
cervical cancer. 
 
Shanta and Krishnamurthi (1980) demonstrated a 65.5% five-year survival rate for treat-
ment of oral cancer with BLM combined with radiation compared with 23.5% for radiation 
alone. In a randomized trial of 104 stage III or IV HNSCC by Fu et al. (1987), patients re-
ceived either radiotherapy alone (Arm A) or radiotherapy with BLM and methotrexate 
(Arm B). The 2-year locoregional control rate and the proportion of distant metastases 
were 26% and 24% in Arm A vs. 64% and 38% in Arm B. However, no significant differ-
ences were present in overall survival curves.  In a trial by Smid et al. (2003), 114 HNSCC 
stage III or IV patients were randomized to receive either postoperative radiotherapy (Arm 
A) or radiotherapy combined simultaneously with mitomycin C and BLM (Arm B). The 
locoregional control at 2 years was 69% in Arm A and 86% in Arm B. The disease-free 
survival was 16% higher and the overall survival 10% higher in the chemoradiotherapy 




Becquerel discovered radioactivity as early as 1896. Since 1971, nuclear medicine has 
evolved dynamically (Graham and Metter 2007, Murdoch and Sager 2008). Many clini-
cally used radionuclides have fallen out of favor, e.g. 81mKr for ventilation imaging and 
99mTc-albumin microspheres for lung perfusion, while other agents, e.g. 18F combined with 
FDG, appear promising (Graham and Metter 2007).  
 
Radionuclides emit gamma-rays, characteristic x-rays, and charged particles. Gamma-rays 
have no mass or electrical charge, and they travel at the velocity of light. In interactions be-
tween high-energy gamma-rays and matter, only a fraction of the energy of gamma-rays 
will be absorbed. The interactions create electrons, which in turn cause ionization effects 
(Johns and Cunningham 1983, Sorenson and Phelps 1987). As a consequence of these in-
teractions, high-energy photons are detected, and they result in radiobiological effects.  




Gamma-ray emitters, such as 99mTc, 111In, and 123I, may be imaged with a single-photon 
emission computed tomography  (SPECT), and positron-emitters, such as 18F and 11C, are 
imaged with positron emission tomography (PET) (Ahonen et al. 2003, Perkins and Frier 
2004). 
 
 In radionuclide therapy, interesting radiations are particulate, e.g. α-, β-, or low-energy 
particles, such as Auger-electrons, while in external beam radiotherapy high-energy pho-
tons or electrons are used (Kassis and Adelstein 2005). Alpha-emitters with their high lin-
ear energy transfer (LET) and short path length are suitable for targeting hematopoietic 
cells, whereas beta-emitters, such as 186Re, 67Cu, 131I, and 90Y, are more suited to solid tu-
mors because of their lower energy and longer path length (Bethge and Sandmaier 2005). 
In certain medullary thyroid carcinomas, high activities (7.4-11.1 GBq) of 131I have been 
proposed again as an adjuvant therapy to total thyreoidectomy (Erdogan et al. 2006, Rufini 
et al. 2008). β-particles destroy cells within a radius of 12 mm. The US Food and Drug 
Administration has approved 90Y-ibritumomab tiuxetan and 131I-tositumomab for the 
treatment of nonHodgkin´s lymphoma (DeNardo et al. 2006).  
 
Auger-electron emitters, such as 123I, 125I, and 111In, emit low-energy Auger-electrons 
which extend from one nanometer to ~ 0.5 µm and are locally absorbed. A few Auger-
emitters are presented in Table 2 (ICRP 1983, Howell 1992, Kassis and Adelstein 2005). 
The linear energy transfer (LET) of the Auger-electrons is more than 20-fold higher than 
the LET observed with energetic β-particles. The electrons of beta decay can extend to ~ 
12 mm and are also locally absorbed (Kassis and Adelstein 2005). The use of therapeutic 
β-particles requires the presence of very high radionuclide concentrations within the tar-
geted tissue. Auger-electron emitters represent an attractive alternative to beta-emitters for 
cancer therapy if they can be located with a proper tracer close to the nuclear DNA (Bodei 




                        Table 2. Auger-electron emitters. 
 
Radionuclides  Half-life β-particles * Auger-electrons 
77Br       57 h 7 7 
123I       13.3 h 11 8 
125I       59.4 days 20 8 
111In     2.8 days 15 8 
114mIn 49.5 days 0 5 
195mPt   4 days 36 8 
                                     * Average number of β-particles per decay 
 
 
2.5. The Auger process 
 
When an electron from the inner shell of certain radioactive atom is removed as a conse-
quence of internal conversion (IC) and/or electron capture (EC), an electron from an outer 
shell immediately fills an inner shell vacancy. The released energy is emitted as character-
istic x-rays or another outer shell orbital electron takes the energy. In this latter Auger 
process, the electron called an Auger-electron is then emitted from the atom instead of 
characteristic x-rays (Sorenson and Phelps 1987). 111In emits on average 15 β-particles and 
8 very short-range Auger-electrons (Howell 1992). Each inner shell electron removal leads 
to characteristic x-rays or Auger-electrons. Generally, an atom emits 5-30 Auger-electrons 
with energies from a few eV to 1 keV (Kassis 2005). When the Auger-electrons deliver 
their energy, the absorbed dose in the decay site within a radius of a few nanometers is of 
the order of 104 – 107 Gy (Kassis and Adelstein 2005).  
 
2.6. Relative biological effectiveness 
 
The International Commission on Radiation Protection (ICRP) formulated the definition: 
“The Relative Biological Effectiveness (RBE) of radiation A with respect to reference ra-
diation R is defined as the ratio of absorbed dose DR in a tissue to the dose DA that causes a 
quantitatively and qualitatively equal effect. Each RBE value derived from a set of obser-
vations for tissue cultures of responses of tissues, in animals or in man, refers to a defined 
end-point, produced under a specified set of exposure conditions” (ICRP 1979). RBE val-
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ues are dependent strongly on the end-point and reference radiation. Earlier, the reference 
radiation was usually 250-keV x-rays. Nowadays, an equivalent dose of 60Co gamma-rays 
or radiation produced in the linear accelerators is easily available. The effectiveness of pro-
ducing biological damage by incorporated radionuclides depends on the nature and energy 
of the radiations as well as on the biokinetics and the subcellular distribution of the ra-
dionuclides (Howell et al. 1993). Faraggi et al. (1994) demonstrated that the absorbed dose 
rate at the center of the cell is 18 times higher if radioactivity of 111In is localized within 
the cell nucleus than if it is situated on the cell membrane. When Auger-emitters are situ-
ated outside or in the cytoplasm of the cell, low-LET radiation effects are shown, RBE 
being about one (Rao et al. 1990, Rao et al. 1991). Auger-electron-emitting radionuclides 
corporated into DNA in the cell nucleus produce high-LET-type effects, with an RBE 
value of  ~ 7-9. In vitro and in vivo experiments with Auger-emitter 111In, which was lo-
calized in the cell nucleus via the radiochemical 111In-oxine, but did not bind to DNA, pro-
duced an RBE value of ~ 4 (Rao et al. 1988, McLean et al. 1989).  RBE has been reported 
to be 7.3 with DNA-incorporated 125I compared with the corresponding value from 250 
keV x-rays for the same cell line (Kassis et al. 1987a). When the decay of 125I is localized 
in the cytoplasm, RBE is ~ 1.3, as in the case of equivalent amounts of beta or gamma 
emission. The DNA-binding 125IdU is about 1.6 times more cytotoxic to V79 cells than 5.3 




111Indium is an Auger-emitter with a half-life of 2.8 days.  111In emits gamma-rays, char-
acteristic x-rays, β-particles, and Auger-electrons. 111In easily forms a complex with BLM 
(Thakur et al. 1973).  111In-BLMC is stable in vitro and in vivo and because it does not bind 
to transferrin it does not cause toxicity to bone marrow (Hou et al. 1984a, Hou et al. 
1984b). Up to 95% of 111In complex activity is excreted via urine within 22 h (Hiltunen et 
al. 1990). 111In-BLMC has been observed to be a tumor-targeting agent in HNSCC, thus 
being a useful tracer (Kairemo et al. 1994, Kairemo et al. 1996a, Kairemo et al. 1996b). 
Tumor-seeking behavior has also been expressed in gliomas (Korppi-Tommola et al. 
1999).  
 
In an autoradiography study by Hou and Maruyama (1992), 78.3% of 111In-BLMC was lo-
calized in the nucleus and nuclear membrane of human small cell lung cancer (SCLC) 
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cells. 111In-BLMC induced more chromosome aberration than BLM (Hou et al. 1992). The 
cytotoxicity of 111In-BLMC has been demonstrated in human small SCLC cell lines (Hou 
et al. 1989a, Hou et al. 1989b). Moreover, in glioma-bearing nude mice, 111In-BLMC di-
minished tumor size better than BLM (Hou et al. 1985). 
 
2.8. Positron emission tomography (PET) 
 
PET is a quantitative imaging modality, that allows observation of metabolic tissue activ-
ity, proliferation, and blood flow (Chin et al. 2006). Glucose metabolism is increased in 
malignant tumors. For example, the uptake of fluorodeoxyglucose (FDG) labeled with a 
positron-emitting 18-fluorine isotope (18F) can be detected by PET (Schmid et al. 2003). At 
present, 18F-FDG-PET is used to detect primary or unsuspected metastatic tumors in clini-
nal practice (Goerres et al. 2004).  
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3. Aims of the study  
 
The purpose of this study was to investigate the suitability of Auger-emitter 111In-labeled 
BLM for diagnosis and potential therapy of HNSCC using in vitro HNSCC cell lines and 
in vivo nude mice and human HNSCC patients.  
Specific aims were as follows: 
 
1. To study the response of HNSCC cells to BLM and external beam radiation. 
 
2. To compare the toxicity of Auger-emitter 111In-BLMC with BLM and 111InCl3 in 
HNSCC cell lines. 
 
3. To investigate wheather the increase of 111In activity in 111In-BLMC enhances the 
cytotoxic effect by comparing two specific activities of 111In-BLMC [40 
MBq/mgBLM (low) and 195 MBq/mgBLM (high)]. 
 
4. To examine the influence of BLM and 111In-BLMC on the cell cycle of HNSCCs. 
 
5. To study the xenografted tumor uptakes of 111In-BLMC. 
 
6. To evaluate whether BLM, especially 111In-BLMC, is toxic and effective in vivo in 
SCC xenografted mice. 
 
7. To determine tumor uptakes of 111In-BLMC and proliferative activities in patient 
data. 
 
8. To compare geometric factors of radionuclide dose distribution (S values, the ab-
sorbed dose in a target organ/region per cumulated activity in a source or-




4. Materials and methods  
 
4.1. Cell lines (I-IV) 
 
The squamous carcinoma cell lines used were obtained from HNSCC patients treated at the 
Department of Otorhinolaryngology – Head and Neck Surgery, Turku University. The 
technique has been described in detail elsewhere (Pekkola-Heino et al. 1991, Pekkola-
Heino et al. 1992a, Lansford et al. 1999). Tumor site, TNM classification, specimen site, 
type of lesion, and earlier therapy are presented in Table 3. 
 
The SCC cells were maintained in Dulbecco´s modified Eagle medium (DMEM) contain-
ing 2 mM L-glutamine, 1% nonessential amino acids, 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 10% fetal bovine serum (FBS). The cells were cultured at 37°C in 5% 
CO2 in a water vapor-saturated atmosphere. The exponential growth of the cells was en-
sured by passing the cells at least weekly. 
 
Table 3.   Tumor site, TNM classification (UICC), specimen site, type of lesion, and 
previous therapy of HNSCC patients. 
 




UT-SCC-2 Floor of mouth T4N1M0 Oral mucosa (P) None 
UT-SCC-8 Supraglottic 
larynx 
T2N0M0 Larynx (P) Radiation 
UT-SCC-9 Glottic larynx T2N0M0 Neck (M) Radiation 
UT-SCC-12A Skin of nose T2N0M0 Skin (P) None 
UT-SCC-12B Skin of nose RT0N1M0 Neck (M)  
UT-SCC-19A Glottic larynx T4N0M0 Larynx (P) None 







4.2. Bleomycin (BLM) (I-IV) 
 
BLM was purchased from Lundbeck Co. (Copenhagen, Denmark) containing 68% fraction 
A2, 30% fraction B2, and 2% other subunits. The stock solution (1 mg/ml) of BLM was 
prepared in calcium- and magnesium-free balanced salt solution and and stored at -20°C. 
 
4.3. 111In-BLMC (II,IV,V)  
 
Radionuclide 111In was chosen for the studies because one of the coauthors (Kalevi 
Kairemo) had performed biodistribution experiments with 111In-BLMC. 111In-BLMC with 
specific activity of 40, 46, 100, or 195 MBq/mg BLM was purchased from MAP Medical 
Technologies Ltd. (Tikkakoski, Finland). At least 98% of 111In activity was bound to BLM.     
 
Preparation of 111In-BLMC is reported elsewhere in detail (Hiltunen et al. 1990, Kairemo 
et al. 1996a). Briefly, the complex was prepared by incubating BLM sulfate dissolved in 
water (2 mg/ml) with 111InCl3 at pH 2-2.5 for at least 30 min. The pH was adjusted with an 
acetate buffer to 6.0. 
 
111In-BLMC was controlled by using thin-layer chromatography (TLC). The composition 
of radiolabeled BLM was studied in detail by separating different BLM fractions first by 
TLC and then by gel chromatography. 
 
 
4.4. 111InCl3 (II)  
  
111InCl3 was purchased from Amersham International plc (Little Chalfont, England). The 
111In activity was 370 MBq/ml. 
 
4.5. Clonogenic assay (I-III) 
 
The experiments with HNSCC cells were performed using the 96-well plate clonogenic as-
say. This technique based on limiting dilutions has earlier been described in detail 
(Grénman et al. 1988a, Grénman et al. 1989). Twenty-four hours before plating, the cells 
were fed with fresh medium. The cells in mid-logarithmic growth (40-60% confluence) 
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were harvested with trypsin-EDTA (315 U/ml trypsin and 0.2 M EDTA) and counted with 
a Bürger chamber after passage through a 25-gauge needle. The cells in Ham´s F-12 me-
dium with 15% FBS were plated immediately onto 96-well plates and moved to a water in-
cubator (37°C, 5% CO2) for a day, as described earlier (Grénman et al. 1988a, Grénman et 
al. 1989). Two to three independent experiments were performed with duplicate plates 
from each cell line for each data point. 
 
In Study I, the cells were irradiated or exposed to given concentrations of BLM. The plates 
were irradiated with four MeV photon irradiation at a dose rate of 2.00 Gy/min using total 
doses of 0.75, 1.25, 2.50, and 5.00 Gy in all cell lines and additionally 7.50 Gy in four of 
the cell lines. The dilutions (1.5-100 nM) of BLM were prepared in the growth medium be-
fore use. 
 
In Study II, chosen concentrations of BLM (1.5-100 nM) and 111In-BLMC (40 or 195 
MBq/mgBLM), at concentrations corresponding to the BLM concentrations, and 111InCl3, 
were added to the 96-well plates. The 111In activity in 111InCl3 corresponded to the 111In ac-
tivity of 111In-BLMC (40 MBq/mgBLM). 
 
In Study III, various concentrations of BLM (1.5n-100nM) were added to the 96-well 
plates. 
 
In all experiments, the plates were incubated for four weeks, and living colonies containing 
at least 32 cells were counted using an inverted phase-contrast microscope. 
 
4.6. Xenograft tumors (III,IV)  
 
UT-SCC-12A and UT-SCC-19A cell lines were injected using 107 cells per site subcutane-
ously into the flank of 6- to 8-week-old balb/c male nude mice (Harlan Laboratories, Great 
Britain). Nude mice were weighed and settled down in micro-isolators with water and 




4.7. In vivo imaging using a gamma camera (IV,V) 
 
Animals 
Tumors of cell line UT-SCC-12A or UT-SCC-19A were grown in the flank of two 6- to 8-
week-old balb/c male nude mice for gamma camera imaging. 
Two xenografted mice were imaged using a Picker Prism 2000 XP single-photon emission 
computed tomography (SPECT) gamma camera equipped with a parallel-hole, medium- 
energy collimator (Picker International, Cleveland, OH, USA). A 256 x 256 x 16 matrix 
size was used, and gamma energies of 111In 173 keV and 247 keV with 20% windows were 
recorded. 
 
The UT-SCC-19A xenografted mouse was imaged at 1, 4, 20, 44, and 95 h after an intrap-
eritoneal 111In-BLMC injection (7.77 MBq/mouse). Planar images of the mouse bearing a 
UT-SCC-12A tumor (904 mm3) were taken 8, 24, 48, and 100 h after injection of 111In-
BLMC. The tumor and the whole body were outlined as regions of interest (ROI), and a 
nontumor ROI was drawn on the contralateral side of the mouse. Activity ratios, total 
counts of the tumor divided by total counts of the whole body (T/w-body), and total counts 
of the tumor in relation to total counts of nontumor regions (T/non-T) were calculated. 
 
Patients 
All patients were generally imaged three times, usually at 1, 4, and 20-24 h after injection. 
A gamma camera (Picker Prism 1500 XP) was used. The matrix size was 128 x 128 x 16, 
and a medium energy collimator for both energy peaks of 111In (173 keV and 247 keV; 
20% windows) was used. 
 
4.8. Experimental therapeutic trial (IV)  
 
The weight of nude mice was 22.7-24.8 g at the beginning of the experiment. Nude mice 
(n=8) with one xenograft tumor each (14-51 mm3) were divided into three groups. The tu-
mor volumes in the control group were 14, 16, 23, and 39 mm3; this group received 
physiological NaCl intraperitoneally. The tumor volumes were 25 and 39 mm3 in the BLM 
group receiving 0.0662 mg BLM/g and 27 and 51 mm3 in the 111In-BLMC group receiving 
111In-BLMC containing 0.0662 mg BLM/g. The treatments were given 6 times over 24 h. 
The total doses were as follows: 0.0126 mg BLM/g every 4 h, 8 h later 0.0081 mg BLM/g 
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at 4-h intervals. In the 111In-BLMC group, the administered total activity was 3.063 
MBq/g.  
 
The nude mice were weighed and the tumor volumes were measured for 14 days two times 
a week in three perpendicular diameters and calculated according to the ellipsoid formula 
(V=π/6*a*b*c). Tumor volume at the time of measurement in relation to tumor volume at 
time of injection  (relative tumor size, RTS) was calculated for every measurement occa-
sion. The logarithmic values were plotted as a function of time.  
 
After the therapy study, pieces of the tumors were frozen in liquid nitrogen for further flow 
cytometric analysis and the rest of the tumors were fixed in formalin and embedded in par-
affin for histopathologic and proliferative activity studies. 
 
4.9. Histopathology and proliferative activity (IV) 
 
A section of each tumor was stained with hematoxylin and eosin for histopathological di-
agnosis and the counting of mitoses. The mitoses were scored as follows: (1) if <2/high 
power field (HPF), (2) if 2-5/HPF, and (3) if >5/HPF.  
 
Staining with rabbit anti-human Ki-67 antigen antibody (dilution 1:150; DAKO, Denmark) 
was performed according to the avidin-biotin complex method as described elsewhere 
(Hsu et al. 1981). More than 1000 cells in at least three fields of magnification x400 (HPF) 
were counted, and positive cells were expressed as a percentage of the total SCC cells. The 
results were scored on a relative scale from 0 to 3 as follows: (0) if 0%, (1) if <15%, (2) if 
15-50%, and (3) if >50%.  
 
4.10. DNA flow cytometry (IV) 
 
This technique has been described in detail in Study IV. Briefly, single-cell suspensions of 
cell lines UT-SCC-2, UT-SCC-12A, and UT-SCC-19A were plated onto 6-well plates (2 x 
104 cells/plate). In addition to control medium cultures, measurements of DNA content 
were performed 24 and 48 h after exposure to BLM (100 nM) and 111In-BLMC (100 nM). 
Stained nuclei with propidium iodide were analyzed in a FACScan flow cytometer (Becton 
Dickinson Immunocytometry Systems, Mountain View, CA), with chicken and trout red 
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blood cells as internal control cells  (Alanen et al. 1989). The percentage of phases G0/G1, 
S, and G2/M of the cell cycle was calculated by MultiCycle software (Phoenix Flow Sys-
tems, San Diego, CA, Autofit version 2.50). DNA histograms of at least 14 000 cells were 
plotted, and a DNA index (DI) was defined to demonstrate DNA ploidy status. 
 
DNA flow cytometry was performed for UT-SCC-12A xenografted tumor samples stored 
in nitrogen liquid. Generally, at least 8000 cells were measured per histogram. The DI and 
the total S phase were defined. 
 
4.11. Data analysis (I-IV)  
 
The plating efficiency (PE) was calculated using the formula PE = - ln (number of negative 
wells/total number of wells)/number of cells plated per well (Thilly et al. 1980). 
The survival fraction (SF) was calculated as follows: 
 
SF = (no. of positive wells/no. of plated cells) x no. of plated cells in control       (1) 
  no. of positive wells in control 
 
SFs as a function of BLM concentration or radiation doses were fitted by the linear quad-
ratic equation F= e-(αD+βD2) using a micro-computer program. The area under the sur-
vival curve (AUC) value, equivalent to the mean inactivation dose (D), was obtained by 
numerical integration. Comparison of chemosensitivity was made using 50% values from 
the dose-response curves (50% inhibition of surviving fraction).   
 
Two to three independent experiments using duplicate plates for each cell line were per-
formed to determine mean and standard deviation (SD) of IC20, IC50, IC90, AUC, and 
SF2 values.    
 
In Study II, null and alternative hypotheses were tested using a paired t-test. P-values were 





In Study III, the doubling time of the xenograft was determined after fitting an exponential 
equation V = k1ek2t. to the dynamic tumor volume data.  
The doubling time TD = (t2-t1) ln2/(lnV2-lnV1) was calculated from the fitted curve, where 
V2 and V1 are volumes at t2 and t1, respectively. 
 
4.12. Patients (V)  
 
Diagnosis and origin of the 10 head and neck tumors used and injected activity of 111In-
BLMC are shown in Table 4. Blood and urine samples were collected at regular intervals 
after injection to estimate clearance of radioactivity. 
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Table 4.  Tumor characteristics in patients. 
 



















3.  76/F SCC 
 
T2N0M0 Tongue, base 
(P) 
8x30x15 75 

















7.  58/F BF - Maxilla 
 
20x15x15 175 












10. 44/M SCC T2N0M0 Tongue (P) 
 
16x9x9 375 
SCC = Squamous cell carcinoma; AC = Adenocarcinoma; BF = Benign fibroma; NL = 
Neurilemmoma; P = Primary tumor; M = Metastasis. 






4.13. Surgery and tumor samples (V) 
 
Tumor samples for radioactivity counting were obtained from operations performed ap-
proximately 48 h after the intravenous injection of 111In-BLMC. Radical tumor removal 
was achieved in all cases. These operations included seven radical or modified neck dis-
sections, two hemiglossectomies, three partial or total laryngectomies, and three local tu-
mor excisions. 
 
Samples of tumor and normal tissues obtained at surgery were processed further while 
fresh. Pieces of the samples were fixed in formalin and embedded into paraffin for histo-
pathological van Gieson and hematoxylin-eosin staining. Fresh tissue samples were 
weighed and radioactivity was counted using an 111In internal standard (LKB 1282 Com-
pugamma; Wallac, Turku, Finland). Samples for immunohistochemistry were prepared in 
Histostix and fast-frozen using liquid nitrogen. Thick sections of the samples were stained 
immediately or stored at –200C.  
 
4.14. Proliferative activity (V) 
 
The proliferative activity was determined by counting the number of mitoses and Ki-67–
positive cells.  For analysis, monoclonal antibody MIB-1 against nuclear antigen Ki-67 
was purchased from Immunotech S.A. (Marseilles, France). A 1:50 dilution of MIB-1 anti-
body was used in an immunoperoxidase technique with avidin-biotin conjugates (Paavonen 
and Renkonen 1992). The frequencies of mitosis and MIB-1 reactivity were scored on a 
relative scale from (1) to (3) as follows: for mitosis activity: (1) if <2/high power field 
(HPF), (2) if 2-5/HPF, and (3) if >5/HPF, for MIB activity: (0) if 0%, (1) if <15%, (2) if 
15-50%, and (3) if >50%.  
 
4.15. Monte Carlo simulation and phantom studies (V) 
 
A Monte Carlo program was originally developed as part of a scheme for systemic radia-
tion treatment, based on quantitative SPET (Ljungberg et al. 1994a, Ljundberg et al 1994b, 
Tagesson et al. 1996). By means of anatomical and isotope images, the program simulates 
photons by following each photon from the decay of the radionuclide until the photon ei-
ther undergoes photoelectric absorption or escapes the phantom/patient, or the photon en-
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ergy drops under a certain cut-off point. In Study V, all regions of interest were larger than 
the electron range, and the electrons were considered locally absorbed. S values for arbi-
trary geometries and all radionuclides may be calculated according to this Monte Carlo 
program. 
Kairemo et al. (1996b) earlier calculated S values of different isotopes of indium (111In, 
111mIn, 113mIn, 114In, 114mIn, and 115mIn) for spherical tumors from the tabulated data in MIR-
DOSE 3 by Stabin (Fig. 1). According to these S values, 114mIn was obviously the best 





Fig. 1.  Calculated S values of different isotopes of indium (111In, 111mIn, 113mIn, 114In, 114mIn, 
and 115mIn) for spherical tumors from the tabulated data in MIRDOSE 3 by Stabin (Kairemo 
et al. 1996b). 
 
MIRD phantom geometry was used to obtain the S values (absorbed dose in a target or-
gan/region per cumulated activity in a source organ/region) for 111In and 114mIn for a real-
istic geometry. A slice through the MIRD phantom is given in Figure 1A of Study V. The 
head and the spine (solid lines) were defined in MIRD pamphlet no. 5 (Snyder et al. 1969), 
and the blood vessels, tumor, and metastases (broken lines) were determined using the CT 
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study of one of the SCC patients (#9/79/F). A coronal slice of the same geometry is shown 
in Figure 1B of Study V.  
 
While tracing the photons, each location of energy depositions was verified, and if an en-
ergy deposition was made inside a predefined region (a MIRD organ or user-defined re-
gion) the absorbed energy of that region was summed. When the session was over, the S 
value was calculated from the absorbed energy of each region. The mass of the region and 
the total number of simulated decays in the source region were taken into account. 
 
4.16. Ex vivo imaging using a beta camera (V) 
 
Images with the beta camera were obtained by mounting the tissue slices on the entrance 
window of the beta camera.  The technique is described in detail elsewhere (Ljunggren and 
Strand 1990). In brief, a light-sensitive detector, a multichannel detector (MCD), was 
equipped with a thin scintillator. When the β-particles were transferred energy to the scin-
tillator material, light photons were created and the position of the β-particles was detected 






4.17. Summary table 
 
Table 5.   Schematically summarized study design. 
 
 
In vitro cell studies 
 
In vivo studies/ animals 
 
In vivo studies/ patients 
 
Comparison of 111In-
BLMC, BLM, 111InCl3, and 
external beam radiation 
 
 
Growth characteristics of 
known cell lines as 
xenografts 
 
Tumor targeting, uptakes 
in HNSCC patients 
 
High-dose 111In-BLMC 
(195 MBq/mgBLM) vs. 




Tumor targeting, uptakes 
in xenografted HNSCC 
 
Dosimetry for HNSCC 
primary and metastatic 
tumor dosimetry for two 
radioisotopes 
 
Effect of BLM and 111In-
BLMC on cell cycle 
 
 
Therapy with 111In-BLMC, 





Ex vivo studies/ animals 
 








Tumor targeting, tissue 















5.1. Cytotoxicity of BLM and external beam radiation (I) 
 
The most significant finding was the variation in the sensitivity for BLM in different SCC 
cell lines, as can be seen in Table 6. Cell lines UT-SCC-19A and UT-SCC-2 differed from 
the others by their chemosensitivities (IC50 = 4.0 ± 1.3 nM, IC50 = 5.2 ± 0.9 nM, respec-
tively). The most chemoresistant cell lines were UT-SCC-12A (IC50 = 14.2 ± 2.8 nM) and 
UT-SCC-9 (IC50 = 11.5 ± 1.1 nM). The survival curves of UT-SCC-2, UT-SCC-8, UT-
SCC-9, UT-SCC-12A, and UT-SCC-19A cell lines are presented in Figure 1 (Study I). 
 
The SF2 values varied between 0.25 ± 0.03 for cell line UT-SCC-9 and 0.38 ± 0.02 for cell 
line UT-SCC-12A (Table 6). Figure 2 shows the radiation survival curves of UT-SCC-2, 




Table 6.   In vitro sensitivity of HNSCC cell lines to BLM and radiation in Studies I-III. 
 









UT-SCC-2 5.2 ± 0.9 (I) 
6.4 ± 0.6 (II) 
 
3.9 ± 0.6 (II) 
 
4.2 ± 0.6 (II) 
0.32 ± 0.05 (I) 1.7 ± 0.1 (I) 
UT-SCC-8 
 
9.4 ± 0.5 (I)   0.37 ± 0.03 (I) 1.9 ± 0.1 (I) 
UT-SCC-9 
 
11.5 ± 1.1 (I)   0.25 ± 0.03 (I) 1.4 ± 0.1 (I) 
UT-SCC-12A 14.2 ± 2.8 (I,III) 
18.8 ± 3.3 (II) 
 
10.7 ± 1.8 (II) 
 
12.7 ± 1.7 (II) 
0.38 ± 0.02 (I) 2.1 ± 0.1 (I) 
UT-SCC-12B 13.0 ± 1.1 (III) 
 
    
UT-SCC-19A 4.0 ± 1.3 (I,III) 
4.1 ± 1.8 (II) 
 
2.0 ± 0.9 (II) 
 
2.6 ± 1.5 (II) 
0.33 ± 0.03 (I) 
 
1.7 ± 0.1 (I) 
IC50, Bleomycin concentration causing 50% inhibition of clonogenic cell survival. 
SF2, Survival fraction after a single radiation dose of 2 Gy. 
AUC, Area under the survival curve
5.2. Cytotoxicity of BLM, 111In-BLMC, and 111 InCl3 in SCC cell lines (II) 
 
The IC50 values for BLM, 111In-BLMC (low), and 111In-BLMC (high) are listed in Table 6. 
The most chemosensitive cell line, UT-SCC-19A, had an IC50 value of 4.1 ± 1.8 nM. The 
IC50 value for 111In-BLMC (low) was 2.0 ± 0.9 nM. 111In-BLMC (high) was more effective 
(IC50 = 2.6 ± 1.5 nM) than BLM, but less effective than 111In-BLMC (low). Differences are 
distinct also in Figure 1 (Study II).  
 
The UT-SCC-2 cell line was chemosensitive (IC50 = 6.4 ± 0.6 nM). The IC50 values for 
111In-BLMC (low) and 111In-BLMC (high) were 3.9 ± 0.6 nM and 4.2 ± 0.6 nM, respec-
tively. In Study II, Figure 2 shows the survival curves of the UT-SCC-2 cell line. 
 
The most chemoresistant cell line, UT-SCC-12A, had an IC50 value of 18.8 ± 3.3 nM. Ex-
periments with this cell line also showed a cytotoxic effect of 111In-BLMC (Study II, Fig-
ure 3). 111In-BLMC (low) and 111In-BLMC (high) had lower IC50 values than BLM, 10.7 ± 
1.8 nM and 12.7 ± 1.7 nM, respectively. 
 
111 InCl3 was not cytotoxic to the three cell lines used (Study II, Figures 1-3). 
 
In testing the IC50 values (N=14) of the three SCC cell lines, 111In-BLMC (low) was a 
more effective cell killer than BLM (p = 0.0016 **). 111In-BLMC (high) was also superior 
to BLM (p = 0.0029 **). Surprisingly, 111In-BLMC (low) was more effective than 111In-
BLMC (high) (p = 0.0023 **). 
 
5.3. SCC cell lines in vitro and in vivo (III) 
  
In in vitro studies, IC20, IC50, and IC90 values varied between the SCC cell lines (Study III, 
Table II). IC50 values for UT-SCC-12A and UT-SCC-12B were 14.2 ± 2.8 nM and 13.0 ± 
1.1 nM, respectively. IC20 values were similar for these two cell lines, whereas a marked 
difference was present in IC90 values, 59.6 ± 2.8 nM and 44.7 ± 1.1 nM (Study III, Table 
II). The most chemosensitive cell line, UT-SCC-19A had an IC50 value as low as 4.0 ± 1.3 
nM. Cell survival data are shown in Figure 1 (Study III).  
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In in vivo studies, the tumors showed growth on the flank in five out of ten animals. Xeno-
grafted mice preserved their vitality and their mean weight increased by 2.8 ± 0.6 g within 
35 days. The tumors started to grow intensively 25 days after SCC cell inoculations. The 
mean tumor volumes are presented as a function of time in Figure 2 (Study III), demon-
strating an exponential pattern of growth. For instance, at 25 and 35 days, the tumor vol-
umes were 111 ± 51 mm3 and 874 ± 577 mm3, respectively. Calculated from the fitted 
curve, the tumor doubling time was 3.86 ± 0.76 days.  
 
5.4. 111In-BLMC in HNSCC xenograft tumors (IV) 
 
5.4.1. Gamma camera imaging     
 
The tumors of the UT-SCC-12A and UT-SCC-19A cell lines are seen in Figure 2 (Study 
IV). Activity ratios of 111In-BLMC on gamma camera images are shown in Table 1 (Study 
IV). The UT-SCC-19A-xenografted mouse had the highest T/non-T uptake ratio of 7.54 at 
4 h after 111In-BLMC injection. The first image of the UT-SCC-12A-xenografted mouse 
was taken at 8 h and showed a T/non-T activity ratio of 5.13. Tumor-to-whole body ratios 
are also provided in Table 1 (Study IV).  
 
5.4.2. Therapeutic trial     
 
During the 14-day trial, no mice died. The relative weight ratios (excluding that of the tu-
mor mass), and the body weight on each examination day divided by the initial weight are 
plotted in Figure 3 (Study IV). The weights were 22.7-24.8 g before the first injections.  
 
The final weight reductions, excluding that of the tumor mass, in the control group were 
3.7%, 5.0%, 5.8% and 9.1%. In the BLM group, the proportions of reductions were 2.7% 
and 4.2%; and in the 111In-BLMC group 2.0% and 4.0%. 
 
The log(RTS) curves of mice, which received  NaCl, BLM, or 111In-BLMC are shown in 
Figure 4 (Study IV). The growth curves flattened out after exposure to BLM and 111In-
BLMC before re-growth 7-9 days after the first injection of the drug. Either of these two 




5.4.3. DNA flow cytometry     
 
Histopathologically, all xenograft tumors consisted of vital carcinomatous squamous cells.  
Less than five mitoses per high power field (HPF) were found in tumors of the NaCl 
group. More than five mitoses per HPF were counted in re-growing tumors of both BLM 
and 111InBLMC groups, as shown in Table 2 (Study IV).  
 
The results revealed the heterogeneity of Ki-67 staining in different tumor regions. The Ki-
67 immunoreactivity was scored as 2 or 3 in three tumors of the NaCl group. Immu-
nostaining remained negative in one tumor. In both the BLM and the 111In-BLMC groups, 
by contrast, Ki-67 nuclear-positive cells formed the majority, and tumor staining was 
scored as 3. 
 
DNA analysis was performed on all tumors. The tumors showed euploidy and aneuploidy, 
as presented in Table 2 (Study IV). The highest flow cytometric aneuploidy values, 1.14 
and 1.15, were obtained in the NaCl group. The total S phase value of the NaCl group 
ranged from 1.51% to 9.21%. The corresponding values for the BLM and 111In-BLMC 
groups were 2.84% and 3.38%; 5.41% and 7.65%, respectively. 
 
The flow cytometry of the three SCC cell lines showed aneuploidy and even tetraploidy in 
cell lines UT-SCC-2 and UT-SCC-19A. The DNA index (DI) of UT-SCC-19A after a one-
day exposure to the diluent, BLM, or 111In-BLMC was 2.03, 2.17, and 2.16, respectively. 
The S phase fractions (SPF) were 45.8%, 42.1%, and 30.9%. The DIs of the cell line UT-
SCC-2 after the same exposure to drugs were 2.84, 2.89, and 2.90, and the SPF values 
24.4%, 24.8%, and 25.7%, respectively. In contrast to the preceding, the DI value of cell 
line UT-SCC-12A was 1.57 in the control, BLM, and 111InBLMC groups.  
 
The cell cycle data were calculated using MultiCycle software. The proportions of G1/G0, 
S, and G2/M phases of three UT-SCC cell lines are shown in Tables 7 and 8. However, the 
proportions of the G2/M phase in cell lines UT-SCC-19A exposed to diluent, BLM, and 
111In-BLMC were 16.1%, 26.8%, and 49.6%, respectively. After two days of exposure to 
drugs, the DNA histogram profile was similar to that after one day of exposure, as shown 




Table 7. Cell cycle data after 24-h exposure to diluent, BLM, or 111In-BLMC. 
 




S phase       
(%) 
UT-SCC-2 diluent 51.7 25.3 23.0 
UT-SCC-2         BLM 45.7 30.5 23.8 
UT-SCC-2 111In-BLMC 43.3 31.4 25.3 
UT-SCC-12A diluent 41.9 22.7 35.4 
UT-SCC-12A BLM 40.6 24.2 35.2 
UT-SCC-12A 111In-BLMC 39.5 27.4 33.1 
UT-SCC-19A diluent 37.7 16.1 46.2 
UT-SCC-19A BLM 31.2 26.8 41.9 




Table 8. Cell cycle data after 48-h exposure to diluent, BLM, or 111In-BLMC. 
 






UT-SCC-2 diluent 73.6 11.4 15.1 
UT-SCC-2 BLM 70.3 14.5 15.2 
UT-SCC-2 111In-BLMC 60.7 19.8 19.6 
UT-SCC-12A diluent 50.8 20.8 28.4 
UT-SCC-12A BLM 50.4 20.8 28.8 
UT-SCC-12A 111In-BLMC 49.0 23.1 27.9 
UT-SCC-19A diluent 47.6 11.0 41.4 
UT-SCC-19A BLM 41.7 15.8 42.5 
UT-SCC-19A 111In-BLMC 26.7 37.9 35.4 
 
 
5.5. Biokinetics of 111In-BLMC implementations for radiochemotherapy (V)  
 
Tumor characteristics and uptake of 111In-BLMC are shown in Table I (Study V). The up-
take was measured as a region of interest (ROI) ratio between tumors and nontumors, cor-
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responding to the location on the contralateral side, from planar gamma camera images. 
The ratio varied from 1.2 to 2.8 in malignant tumors, and was 1.0 in one benign tumor 
(#7/58/F). The uptake of 111In-BLMC was unaffected by the fivefold increase in injected 
radioactivity dose. The tumor grades, frequency of mitoses, and proliferation grades were 
in close correlation with each other, varying between 1 and 3 in malignant tumors and were 
all graded 0 in benign tumors (Table 9). Moreover, an evident correlation existed between 
grade and uptake of 111In-BLMC (correlation coefficient R = 0.566).      
 
The effective half-life, 
    
    T1/2,eff = (t1/2,phys · t1/2,biol) / (t1/2,phys + t1/2,biol)   (2) 
 
where t1/2,,phys and t1/2,biol are the physical and biological half-lives, for radioactivity was 
1.5-3.1 h in serum and 1.4-3.7 h in urine. About half of the activity was excreted in urine 
within 3 h, and more than 95% within 22 h. Tumor sample uptakes varied between 0.1 and 
0.95 x 10-3% of injected dose (ID/g at 48 h) in malignant tumors. In benign fibroma, the 
uptake was 0.06 x 10-3% of injected dose (ID/g at 48 h). Measured absolute uptakes in tu-
mor samples correlated with 111In-BLMC uptake on images (R = 0.705). The uptake of 
111In-BLMC, measured from tumor samples, correlated with the frequency of mitoses (R = 
0.734) and the grade of proliferation (R = 0.846). The effective half-life for tumor tissue 
varied from 16 to 49 h. 
 
S values were obtained for the regions and organs of interest in images (Study V, Table II). 
Tumor (user-defined), metastasis (user-defined), total body, kidneys, and liver were used 
as source organs/regions when tumor dose was calculated from the computed tomographic 
(CT) and SPET data for one SCC patient (#9/79/F). The thyroid was considered a target 
organ. MIRD pamphlet no.11 published S values, which were converted into Gy/MBqh, 
are presented in Table II (Study V). Our simulated S values for 111In and 114mIn and the ra-
tios of S values for 114mIn to 111In are shown in the same table. For example, the calculated 
S value for internal tumor dose  (Tumorsource→ Tumortarget) was 2.04x10-3 Gy/MBqh for 




The physical half-life differs between the two radionuclides (2.8 days for 111In and 49.5 
days for 114mIn). Thus, the effective half-lives differ widely, assuming the same biological 
half-life.  
 
The ratio (114mIn /111In) of the effective half-lives is 1.6 when the biological half-life is 2 
days. The ratio becomes 3.8 with a biological half-life of 10 days. 
 
In the kidneys, the dosimetric estimate for a 3700 MBq dose was 2.2 Gy (tolerance 20 Gy), 
when the mean residence time (MRT), determined from the imaging data, was 5 h. When 
assuming an MRT of 16 h in a 14-g tumor (MIRD formalism), the tumor dose was 0.66 
cGy/MBq. Patient #9/79/F had a tumor of this size, and MRT in this case corresponds to 
the shortest half-life observed in the tumor.  
The SCC tissue slices, containing approximately 111In-BLMC 1 kBq/g, were imaged with a 
beta camera for 6-8 h. The activity at 48 h was distinctly concentrated in the malignant tu-
mor (yellow areas), representing an SCC of the tongue base (Study V, Figure 2A). In Fig-
ure 2B, which represents a low-grade mesenchymal malignant tumor, the overall activity 
was significantly lower than in Figure 2A (Study V, Figure 2B). Heterogeneous uptakes in 
tissue slices can be observed in beta camera images also within the tumor. 
 
Table 9. Patient data. 
 




175 MB  
 (3 patients) 
Injected activity 
375 MBq 
 (3 patients) 
Blood T1/2 (h) 1.5 – 1.9  1.9 – 3.1  1.8 – 2.1  
Tumor T1/2 (h) 20 – 49  29 – 34  16 – 30 
Absolute tumor 
uptake 
 (%ID/g x10-3) 
0.11 – 0.95 0.06 – 0.58 0.22 – 0.9 
Tumor uptake 1.4 – 2.8 1.0 – 1.5  1.2 – 1.6  
Mitoses 2; 2; 3; 3; 3; 3 0; 3; 1 1; 3; 3; 2 
Ki-67 staining 2; 1; 2; 3; 3; 3 0; 2; 1 1; 3; 3; 3  
Grade 2; 2; 3; 3; 3; 3 0; 3; 1 1; 3; 3; 3  
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6. Discussion  
 
Head and neck squamous cell carcinoma is the sixth most common cancer in the world, 
and approximately two-thirds of HNSCCs are in stage III/IV at presentation. In Finland, 
HNSCCs represent 2.6% of all new malignancies (Finnish Cancer Registry 2006).  Despite 
combined modality therapies, including surgery, external radiation, and chemotherapy, the 
5-year overall survival rate of stage III and IV disease remains at 40%. Novel approaches 
such as nuclear medicine, are needed to improve patient outcome.  
 
In this thesis, we have studied the usefulness of 111In-BLMC in the diagnostics and therapy 
of HNSCC using in vitro HNSCC cell lines and in vivo nude mice and also (human) 
HNSCC patients. 
 
6.1. Cytotoxicity of BLM, external beam radiation, 111In-BLMC, and 111 InCl3 in 
HNSCC cell lines in vitro (I-IV) 
 
The 96-well plate clonogenic assay is a suitable method for studying HNSCC cell lines, as 
has been shown in several reports (Grénman et al. 1988a, Pekkola-Heino et al. 1989, 
Grénman et al. 1989, Pekkola-Heino et al. 1992a, Erjala et al. 2006). The cell culture based 
on limited dilutions reveals living cell colonies well. Up to 10-fold PE values have been 
observed with this method, as compared with soft agar methods. In our study, the plating 
efficiencies varied from 0.1 to 0.55. The most chemosensitive cell line, UT-SCC-19A, had 
the lowest plating efficiency. However, plating efficiency had no impact on cytotoxicity.   
 
Studies I and III 
 
In the literature, the sensitivity for BLM differs considerably between cell lines, from 5- to 
10-fold (Urade et al. 1992). Studies have also indicated variation in inherent radiation sen-
sitivity (Weichselbaum 1986, Grénman et al. 1988b, Pekkola-Heino et al. 1989).  
 
Study I and the in vitro part of Study III confirmed earlier results of variation in SCC cell 
lines with respect to sensitivity for BLM (Table 6). In Study III, we used two HNSCC cell 
lines (UT-SCC-12A and UT-SCC-12B) that originated from a primary tumor and metasta-
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sis of the same patient. The cell line UT-SCC-12B from the metastasis had an IC50 value 
of 13.0 ± 1.1 nM. The UT-SCC-12A of the primary tumor had an IC50 value of 14.2 ± 2.8 
nM.  
 
In Study I, differences in the IC50 values for BLM and the SF2 values for irradiation be-
tween the most sensitive and resistant SCC cell lines were 3.6- and 1.7-fold, respectively. 
UT-SCC-12A with a high IC50 value for BLM (IC50 = 14.2 ± 2.8 nM) also had a high 
SF2 value for radiation (SF2 = 0.38 ± 0.02).  The most chemosensitive cell line, UT-SCC-
19A (IC50 = 4.0 ± 1.3 nM), had an SF2 value of 0.32 ± 0.03. The UT-SCC-9 cell line had 
an IC50 value of 11.5 ± 1.1 nM for BLM, but had the highest sensitivity for radiation (SF2 
= 0.25 ± 0.03). This may indicate that the mechanisms for radio- and chemoresistance are 
at least partially different. More than one mechanism is generally likely to be responsibible 
for the resistance. BLM hydrolase converts BLM to an inactive desamino form, probably 
explaining the primary mechanism of BLM resistance (Lazo et al. 1982). Another mecha-
nism may be elevated DNA repair activity (Iqbal et al. 1976, Dar and Jorgensen 1995).  
 
External beam radiation has extensively been combined with DNA-active chemotherapeu-
tics in the treatment of head and neck cancer. The rationale has been to get a benefit from 
the combination with the hope of a positive interaction, based on a similarity in the mecha-
nism of action for each separate agent. An additive effect of carboplatin and radiation, pa-
clitaxel and radiation, and vinorelbine and radiation has been reported (Pekkola-Heino et 
al. 1992b, Pulkkinen et al. 1996, Erjala et al. 2004).  
 
Study I was initiated to investigate the chemo- and radiosensitive elements separately in 
vitro. The results showed that HNSCC cells respond to both BLM and external beam ra-
diation. Our data provide a good basis for further in vitro and in vivo experiments to char-






Concurrent chemoradiotherapy has proven more effective than neoadjuvant and adjuvant 
schedules in improving patient outcome (Pignon et al. 2000, Bernier and Bentzen 2002, 
Bourhis et al. 2007, Pignon et al. 2007). Two independent, large-scale prospective random-
ized trials demonstrated that simultaneous cisplatin and irradiation were more effective in 
control of locoregional disease and yielded longer disease-free survival than radiotherapy 
alone (Bernier et al. 2004, Cooper et al. 2004). This suggests that combining the radionu-
clide with a chemotherapeutic agent has the potential to improve patient outcome. Che-
motherapeutic agents are likely to inhibit the repair of lethal and sublethal damage caused 
by radiation. They probably also radiosensitize hypoxic cells and synchronize tumor cells 
into the G2/M phase, which is the most radiosensitive phase of the cell cycle (Bernier and 
Cooper 2005).   
 
BLM has been reported to function as a radiosensitizer in benign and malignant tumors 
(Orford et al. 1995, Sung et al. 1995). In a trial by Smid et al. (2003), locoregional control 
at 2 years was 69% in postoperative radiotherapy alone compared with 86% in radiother-
apy combined simultaneously with mitomycin C and BLM. 
 
Radiation affects cells at the DNA level, resulting in cell cycle disturbances and arrest in 
the G2 phase, which diminishes cell divisions. Furthermore, BLM is known to be active at 
the DNA level, causing single- and double-strand breaks. Even-Sapir et al. (1994) have 
demonstrated that the uptake of 57Co-BLM predicts the outcome of lung cancer patients. 
They found that patients with lung cancers, with a high uptake of 57Co-BLM bound into 
the DNA after injection responded poorly to chemotherapy and had a shorter survival than 
patients with tumors showing lower uptake. BLM complexes are conceivable for therapy 
because of unexpectedly good targeting characteristics. We found a good sensitivity (93%) 
and specificity (100%) in the diagnostic staging of 13 head and neck cancer patients using 
a low-pH 111In-BLMC (Kairemo et al. 1994). 111In is a gamma-emitter with an energy of 
two gammas (171 keV and 245 keV), but it also emits Auger-electrons suitable for thera-




Study II clearly demonstrated that 111In-BLMC (low) was more toxic to HNSCC cells than 
BLM in all three cell lines tested (Table 6; Study II, Figures 1-3). For UT-SCC-2, UT-
SCC-12A, and UT-SCC-19A, the IC50 ratios between BLM and 111In-BLMC (low) were 
1.6-fold, 1.8-fold, and 2.1-fold, respectively. The differences between BLM and 111In-
BLMC (high) in the above-mentioned cell lines were 1.5- to 1.6-fold, 111In-BLMC (high) 
being more toxic. 111In activity (40 MBq/mg BLM) was more effective in killing cells than 
111In activity (195MBq/mg BLM). An almost fivefold increment of 111In activity of the 
complex did not increased cytotoxicity.  Clinically, specific activities of 40-100 MBq/mg 
BLM have been used. Higher 111In activities, such as 195 MBq/mg BLM, have not been 
used in patients. Obviously, the relative biological effectiveness (RBE) of Auger-electrons 
is high using 111In-BLMC (low). This may mean, that when the saturation concentration is 
reached, the addition of 111In activity will not increase cytotoxicity. Higher radioactivity 
doses may damage the properties of BLM. Superfluous labeling might cause radiolysis, 
with a similar effect as immunoreactivity in labeling of antibodies.   
 
In vitro and in vivo experiments with Auger-emitter 111In, which was localized in the cell 
nucleus via the radiochemical 111In-oxine, but did not bind to DNA, produced an RBE 
value of ~ 4 (Rao et al. 1988, McLean et al. 1989). RBE has been shown to be 7-9 for 125I, 
whereas it is considered to be 1 for external beam radiation (Howell et al. 1993, Narra et al. 
1994). In addition to the nature and energy of the radiation, the effectiveness of producing 
biological damage via radionuclides depends on biokinetics and subcellular distribution. 
Auger-electrons deliver their energy, 104 – 107 Gy/decay, within a radius of one nanometer 
to 0.5 μm around the decay site (Kassis and Adelstein 2005). Faraggi et al. (1994) demon-
strated that the absorbed dose rate at the center of the cell is 18 times higher if radioactivity 
of 111In is localized within the cell nucleus than if it is situated on the cell membrane. The 
close proximity of the Auger-electron-decaying atom to DNA leads to high-LET-type ra-
diation effects. This has been confirmed by in vitro studies; the Auger-emitter bound to 
nuclear DNA has caused a monoexponential decrease in survival (Kassis et al. 1987b), 
while decay within the cytoplasm or extracellularly has produced survival curves typical of 
x-rays (Kassis et al. 1987a).      
 
111InCl3 was not cytotoxic in this study. Hou et al. (1989a) demonstrated a corresponding 




111In-BLMC, which has a tumor-seeking and DNA-splitting nature, has an in vitro synergy 




BLM is known to be active at the DNA level, causing single- and double-strand breaks 
(Iqbal et al. 1976, Kohn and Ewig 1976, Cheong and Iliakis 1997). Some investigators 
have reported an ability of BLM to block cells reversibly in the G2 phase (Barranco et al. 
1973b, Constanzi et al. 1976).  However, BLM is not generally considered to induce al-
terations in the cell cycle, as is the case with paclitaxel. Paclitaxel clearly produced a G2/M 
block in the cell cycle of cell line UT-SCC-19A (Elomaa et al. 1995).  
 
The flow cytometric results of the three UT-SCC cell lines used were interesting. In all cell 
lines, the percentage of cells in the G2/M phase increased after exposure to BLM, espe-
cially 111In-BLMC (Tables 7 and 8). In Study I, cell line UT-SCC-19A was more sensitive 
to BLM and external radiation than cell lines UT-SCC-2 and UT-SCC-12A. In Study IV, 
the proportion of UT-SCC-19A cells in the G2/M phase was 16.1%, 26.8%, and 49.6% in 
the control, BLM, and 111In-BLMC groups, respectively (Study IV, Figure 5). By contrast, 
the proportion of cells in the G0/G1 phase appeared to diminish from 37.7% in the control 
group to 31.2% in the BLM group and 17.9% in the 111In-BLMC group. A corresponding 
tendency was seen with the UT-SCC-2 and UT-SCC-12A cell lines. 
Our results suggest that BLM and particularly 111In-BLMC seem to induce alterations in 
the cell cycle by producing a G2/M block. The G2/M phase of the tumor cell cycle is the 
most sensitive to irradiation (Sinclair 1968). In a flow cytometric study, Sham and Durand 
(1999) observed a radiation-induced G2 block after external beam radiation of human cer-
vical SCC xenograft tumors in SCID mice. 
 
6.2. 111In-BLMC in SCC xenograft tumors (III, IV)  
    
An urgent need exists to develop strategies for the diagnostics and treatment of HNSCC.  
Genetic engineering in mouse models for HNSCC has recently progressed (Lu et al. 2006). 
Experimental mouse models recapitulate the growth of human HNSCCs. For example, 
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comparison of the effect between different therapies yields important information, al-




Xenografted mouse experiments are sensitive to disturbances. Thus, a 50% tumor growth 
in the flank was acceptable in Study III. Between days 25 and 35, growth of the tumors 
was rapid, the doubling time being 3.9 days. This result gave a good basis for further tumor 
xenograft experiments in Study IV, particularly for dose planning in treatment with 111In-
BLMC.  
 
In subsequent studies, cytotoxicity might be increased using Auger-emitting BLMC in 
combination with electrochemotherapy (ECT). ECT is an antitumor approach that com-
bines systemic BLM with electric pulses (EPs) delivered locally at the tumor site. EPs in-
crease the permeability of the cell membrane in the tissue, allowing BLM delivery inside 




In the imaging study, xenografted tumors of cell lines UT-SCC-12A and UT-SCC-19A 
were observed in planar images (Study IV, Figure 2). Hou et al. (1984a, 1984b) demon-
strated 111In-BLMC affinity to viable tumors in glioma-bearing mice.  
 
In the therapeutic study, after the weight loss correction, the final loss in the two cell lines 
turned out to be 2.7% and 4.2% in the BLM group and 2.0% and 4.0% in the111In-BLMC 
group (Study IV, Figure 3). Thus, a 15% weight loss, which is usually considered a signifi-
cant indicator for maximum tolerated dose in preclinical radionuclide therapy trials, was 
not achieved. Tumors receiving BLM and 111In-BLMC showed a flattening of their growth 
curves, whereas control tumors reached exponential growth (Study IV, Figure 4). In addi-
tion, seven of eight tumors showed regrowth at the time animals were sacrificed. Sham and 
Durand (1999) investigated cell kinetics and repopulation parameters of xenografts in 
SCID mice using continuous or split course external irradiation. The regrowth rate of these 





Based on Ki-67 antigen activity and number of mitoses, the proliferative activity was 
stronger in the BLM and 111InBLMC groups than in the NaCl group, indicating regrowth 
of the tumors (Study IV, Table 2). Heterogeneity in Ki-67 staining was observed. Variation 
in proliferation and cellular differentiation in different tumor regions of HNSCC has been 
shown  (Jacob et al. 1996). Flow cytometry expressed a slight difference in ploidy status, 
which was not typical of any given therapy group. 
 
The beneficial effect of BLM has consistently been demonstrated in experiments using 
xenografted HNSCCs (Wahlberg et al.1987, Elprana et al. 1992). Radioactive (191Pt) cis-
platin has been shown to be more effective than cisplatin alone in decreasing tumor size in 
nude mice (Areberg et al. 2001). The efficacy of a 186Re-labeled monoclonal antibody has 
been shawn in HNSCC and ovarian cancer xenografts, this antibody can be used to cause a 
total ablation of these tumors (Gerretsen et al. 1993, Kievit et al. 1997).  
 
Some in vivo therapy studies with DNA-incorporated Auger-electron-emitting radionu-
clides have demonstrated excellent results in (Baranowska-Kortylewicz et al. 1991). A 5-
log reduction in intraperitoneal ascites ovarian cancer cell survival has been observed in 
mice treated with 125I-UdR (Bloomer and Adelstein 1977). In another therapy study, rats 
with intrathecal tumors received therapeutic doses of 125I-UdR intrathecally and in addition 
to methotrexate; 5- to 6-log tumor cell reduction and 30% improvement in tumor-bearing 
rats was shown (Kassis et al. 2004). 
 
In this study, BLM and 111In-BLMC were more effective than NaCl in reducing tumor size 
in HNSCC (Study IV, Figure 4). Hou et al. (1985) tested 111In-BLMC therapy in glioma-
bearing mice and found 111In-BLMC to be superior to BLM in reducing tumor size. 
 
However, a thorough comparison between the BLM and 111In-BLMC groups in this study 
could not be conducted due to the small number of mice. Our findings should, however, 
provide impetus for further experiments concerning therapeutic applications using more 
animals and possibly with more radio- and chemosensitive cell lines. Dose and schedule of 









This study confirms the tumor-seeking behavior of 111In-BLMC in HNSCC (Table 9; 
Study V, Table I) shown in our previous patient study (Kairemo et al. 1996b). Table 9 
clearly demonstrates that uptake of 111In-BLMC was unaffected by a fivefold increment in 
injected radioactivity. A set level of uptake was achieved with the lower doses. In the pa-
tient study, the specific activity of the complex was the same, 100 MBq/mg BLM. In the in 
vitro study there were two specific activities, 40 MBq/mg BLM and 195MBq/mg BLM, of 
the complex. Interestingly, an almost fivefold increment of 111In activity did not increase 
cytotoxicity.  
 
Using diagnostic doses of 111In-BLMC (75-375 MBq), no side-effects were seen in head 
and neck cancer patients. The uptake ratio received from gamma images varied from 1.2 to 
2.8 in malignant tumors, and was 1.0 in the benign tumor. Under certain conditions, it 
might be possible to distinguish benign disease from malignant disease. An obvious corre-
lation existed between the grade and the uptake of 111In-BLMC (Table 9).  Even-Sapir et 
al. (1994) demonstrated that the uptake of 57Co-BLM predicts the outcome of lung cancer 
patients. They found that patients with lung cancer tumors who had a high uptake of 57Co-
BLM responded poorly to chemotherapy and had a shorter survival time than patients with 
tumors showing a lower uptake. 
 
The tumor grade, frequency of mitoses, and proliferation grade, measured using MIB im-
munohistochemistry, were in close correlation with each other and varied between 1 and 3 
in malignant tumors, and were all graded 0 in the benign tumor (Table 9). Malignant tu-
mors with strong proliferation activity and poor prognosis might have higher uptake of the 
radiochemotherapeutic agent. This information could be useful in therapy planning. 
 
The effective half-lives for radioactivity in serum and urine are consistent with the results 
of others (Crooke et al. 1977, Kramer et al. 1978). Labeling of BLM did not essentially 
change the serum half-life or the plasma clearance rate. The effective half-life for the tu-
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mor tissue varied between 16 and 49 h. This shows an overall rapid clearance rate from 
normal organs and slower clearance from targeted tumor tissue. 
 
Heterogeneous uptake of 111InBLMC within the tumor and between the tumors was ob-
served in beta camera images (Study V, Figures 2A and 2B).  
 
The kidneys were considered to be a critical organ. The estimate for a 3700 MBq dose, as-
suming a mean residence time (MRT) of 5 h (blood), was 2.2 Gy, which is under the toler-
ance dose of 20 Gy. The tumor dose was 0.66 cGy/MBq, when assuming a MRT of 16 h, 
in a 14-g tumor (MIRD formalism). In this case, the total tumor dose would be 24.4 Gy, 
corresponding to the tumor size of patient  #9/79/F. MRT in this case was similar to the 
shortest half-life observed in tumor samples. 
 
Radionuclide-based therapy requires a suitable carrier, appropriate physical properties of 
the radionuclide, and knowledge of the interaction between the radionuclide-based agent 
and its biological environment. Theoretically, substituting 111In with 114mIn might lead to a 
better cytotoxic effect because of the higher energy of Auger-electrons and a longer half-
life of 49.5 days. Regarding the S values for 111In and 114mIn, i.e. the absorbed dose in a 
target region per cumulated activity in the source organ, 114mIn seems to give higher ab-
sorbed doses at short ranges. We simulated S values for 111In and 114mIn, and with ratios of 
S values for 114mIn to 111In, in Gy/MBqhs. The calculated ratio of the S values for 114mIn to 
111In (Tumorsource→ Tumortarget) was 16.127 (Study V, Table II). The ratio of the S values 
for 114mIn to 111In (Total bodysource→ Total bodytarget) was 4.135. Thus,  [S(Tumor)/S(Total 
body)]In-114m/[S(Tumor)/S(Total body)]In-111 was approximately 4. 
 
Rapid advances are being made in the field of targeted radionuclide therapy. Auger-
electron emitters, e.g. 111In and 114mIn, represent an attractive alternative in the treatment of 
advanced HNSCC. The possibility exists of finding even more effective carriers, such as 
nanoparticles, which would bring the Auger-emitters in very close proximity to DNA.  
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7. Conclusions   
 
In this thesis, in vitro and in vivo suitability of the Auger-emitter 111In-labeled BLM for di-
agnosis and potential therapy of HNSCC was demonstrated as follows: 
 
1. The response of HNSCC cells to BLM and external beam radiation in vitro was 
demonstrated. We also found variation in the sensitivity for BLM and external beam 
radiation in different HNSCC cell lines. One cell line was sensitive to radiation, but not 
to BLM. 
 
2. The Auger-emitting 111In-BLMC was more toxic than BLM in all three tested 
HNSCC cell lines, indicating the synergistic nature of 111In-BLMC.  
 111InCl3 alone was not cytotoxic.  
 
3. 111In activity of 40 MBq/mg BLM was more effective in killing cells than 111In ac-
tivity of 195MBq/mg BLM. An almost fivefold increment of 111In activity did not in-
crease cytotoxicity. In fact, the increase of 111In activity in 111In-BLMC weakened the 
cytotoxic effect.  
 
4. In all cell lines, the percentages of cells in the G2/M phase increased after exposure 
to BLM, especially to 111In-BLMC. BLM and particularly 111In-BLMC seemed to in-
duce alterations in the cell cycle by producing a G2/M block. 
 
5. The activity ratios of 111In-BLMC expressed tumor-seeking behavior in UT-SCC-
12A and UT-SCC-19A xenografted mice. The xenograft tumors of cell lines UT-SCC-
12A and UT-SCC-19A were also observed in planar images.  
 
6. Tumors receiving BLM and 111In-BLMC showed a flattening of their growth curves, 
indicating the cytotoxic effect of the drugs, whereas control tumors reached exponen-
tial growth. However, a thorough comparison between BLM and 111In-BLMC groups 




7. The uptake ratios revealed by gamma images indicated tumor-seeking behavior of 
111In-BLMC. Measured absolute uptakes in tumor samples correlated with 111In-BLMC 
uptakes on images. The uptake of 111In-BLMC was unaffected by a fivefold increment 
in injected radioactivity. A positive correlation existed between 111In-BLMC uptake, 
Ki-67/MIB activity, and number of mitoses.    
  
8. Judging from the S values for 111In and 114mIn, which indicate the absorbed dose in a 
target region per cumulated activity in a source organ, 114mIn seemed to give higher ab-
sorbed doses at short ranges, and thus, cytotoxicity might be more effective with 
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